CervoMed (CRVO) Change in Account Payables (2010 - 2026)
CervoMed (CRVO) posted Change in Account Payables of $765364.0 for Q1 2026, up 706.5% sequentially from $94899.0 in Q4 2025, and up 119.2% YoY from $349158.0 in Q1 2025.
CervoMed (CRVO) Change in Account Payables (2010 - 2026) Analysis & Trends
CervoMed has reported Change in Account Payables for 9 years, with the latest figure at $765364.0 in Q1 2026.
- Quarterly Change in Account Payables rose 119.2% year-over-year to $765364.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $348884.0 (down 75.58% YoY) and the FY2025 annual result came in at -$67322.0, down 107.93% from the prior year.
- Change in Account Payables grew to $765364.0 in Q1 2026 per CRVO's latest filing, from $94899.0 in the prior quarter.
- Over five years, Change in Account Payables peaked at $765364.0 in Q1 2026 and troughed at -$434813.0 in Q3 2025.
- A 4-year average of $162475.4 and a median of $240257.0 in 2023 frame the typical range for Change in Account Payables.
- The sharpest annual moves came in 2024 and 2025: Change in Account Payables surged 453.47% in 2024, then slumped 221.94% in 2025.
- Over 4 years, Change in Account Payables stood at $182494.0 in 2023, then soared by 135.08% to $429005.0 in 2024, then plunged by 77.88% to $94899.0 in 2025, then jumped by 706.5% to $765364.0 in 2026.
- According to Business Quant data, Change in Account Payables over the past three periods registered $765364.0, $94899.0, and -$434813.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -66.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -8.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 37.53 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | CervoMed | 26.64 Mn | 26.64 Mn | - | -1.53 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -1.53 Mn |
| Jun 30, 2026 | -1.53 Mn |
| Mar 31, 2026 | 765,364.00 |
| Mar 31, 2026 | 765,364.00 |
| Dec 31, 2025 | 94,899.00 |
| Dec 31, 2025 | 94,899.00 |
| Sep 30, 2025 | -434,813.00 |
| Sep 30, 2025 | -434,813.00 |
| Jun 30, 2025 | -76,566.00 |
| Jun 30, 2025 | -76,566.00 |
| Mar 31, 2025 | 349,158.00 |
| Mar 31, 2025 | 349,158.00 |
| Dec 31, 2024 | 429,005.00 |
| Dec 31, 2024 | 429,005.00 |
| Sep 30, 2024 | 356,581.00 |
| Sep 30, 2024 | 356,581.00 |
| Jun 30, 2024 | 293,786.00 |
| Jun 30, 2024 | 293,786.00 |
| Mar 31, 2024 | -230,403.00 |
| Mar 31, 2024 | -230,403.00 |